Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1044 | 1022 | 1010 | 1060 | 1339 | 2245 |
Fund Return | 4.41% | 2.18% | 0.99% | 1.97% | 6.01% | 8.42% |
Place in category | 139 | 431 | 251 | 250 | 70 | 5 |
% in Category | 22 | 65 | 42 | 45 | 16 | 3 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pictet CH Institutional Swiss EquZD | 1.58B | 3.74 | 2.02 | 7.33 | ||
Pictet CH Institutional Swiss EquiI | 1.58B | 6.08 | 2.73 | 7.19 | ||
Pictet CH Institutional Swiss EquiP | 1.58B | 6.02 | 2.53 | 6.98 | ||
Pictet CH Institutional Swiss EquiZ | 1.58B | 2.66 | 4.28 | 7.37 | ||
Pictet CH Institutional Swiss EquID | 1.58B | 2.58 | 3.78 | 6.87 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.43B | 3.85 | 3.74 | 6.24 | ||
Raiffeisen Futura Swiss Stock A | 2.13B | 2.12 | 2.41 | 6.12 | ||
UBS CH Equity Fund Swiss Income CHF | 2.1B | 2.43 | 3.56 | 5.81 | ||
UBS CH Equity Fund Swiss Income CHQ | 2.1B | 2.59 | 4.20 | 6.41 | ||
UBAM Swiss Equity AD CHF Inc | 1.78B | 7.99 | -0.55 | 5.90 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nestle | CH0038863350 | 13.82 | 95.00 | -0.19% | |
Roche Holding Participation | CH0012032048 | 9.98 | 227.60 | +1.11% | |
Novartis | CH0012005267 | 9.60 | 93.07 | +0.81% | |
Richemont | CH0210483332 | 7.29 | 134.70 | -0.59% | |
Zurich Insurance Group | CH0011075394 | 6.21 | 455.00 | -0.52% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | BUY | Strong Buy | Strong Buy |
Summary | Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review